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CIC (also known as Capicua) is a transcriptional repressor negatively regulated by RAS/MAPK signaling. Whereas
the functions of Cic have been well characterized in Drosophila, little is known about its role in mammals. CIC is
inactivated in a variety of human tumors and has been implicated recently in the promotion of lung metastases.
Here, we describe a mouse model in which we inactivated Cic by selectively disabling its DNA-binding activity, a
mutation that causes derepression of its target genes. Germline Cic inactivation causes perinatal lethality due to
lung differentiation defects. However, its systemic inactivation in adult mice induces T-cell acute lymphoblastic
lymphoma (T-ALL), a tumor type known to carryCICmutations, albeit with low incidence.Cic inactivation inmice
induces T-ALL by a mechanism involving derepression of its well-known target, Etv4. Importantly, human T-ALL
also relies on ETV4 expression for maintaining its oncogenic phenotype. Moreover, Cic inactivation renders T-
ALL insensitive toMEK inhibitors in bothmouse and human cell lines. Finally, we show that Ras-inducedmouse T-
ALL as well as human T-ALL carrying mutations in the RAS/MAPK pathway display a genetic signature indicative
of Cic inactivation. These observations illustrate that CIC inactivation plays a key role in this human malignancy.
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Ras proteins have been the subject of intense investiga-
tion due to their key role in mitogenic signaling (Malum-
bres and Barbacid 2003). Genetic studies have provided
evidence that Ras signaling is essential for mammalian
cell proliferation (Drosten et al. 2010). However, constitu-
tive activation of individual members of the downstream
mitogen-activated protein kinase (MAPK) pathway, in-
cluding the Raf, Mek, and Erk kinases, can bypass the re-
quirement for Ras proteins (Drosten et al. 2010). However,
little is known regarding those events that take place be-
yond MAPK signaling, in part due to the complexity of
the events triggered by this kinase cascade in which just
the Erk proteins alone are known to phosphorylate >150
substrates (Roskoski 2012).
While searching for potential downstream effectors of
the MAPK pathway, the Drosophila protein Capicua
(Cic) (Jiménez et al. 2000) came to our attention. Cic pro-
teins are evolutionarily conserved transcriptional repres-
sors that directly bind DNA via their HMG-box with the
assistance of a C-terminal motif (Forés et al. 2017). Both
the Drosophila and mammalian Cic loci express short
(Cic-S) and long (Cic-L) protein isoforms that are tran-
scribed from two independent promoters (Lam et al.
2006; Jiménez et al. 2012; Forés et al. 2015). Moreover,
DrosophilaCic proteins have a docking site that allows di-
rect binding of Rolled, the Drosophila counterpart of the
mammalian Erk kinases (Astigarraga et al. 2007). Cic re-
pressor activity is down-regulated by receptor tyrosine ki-
nase-mediated MAPK signaling (Jiménez et al. 2012). In
Drosophila, theCic locus has been implicated in a variety
of developmental processes such as antero–posterior or
dorso–ventral patterning of the embryo (Jiménez et al.
2000), specification of wing veins (Roch et al. 2002), and
tissue growth in various contexts. Indeed, during cell pro-
liferation of both larval tissues and adult intestinal stem
cells, the mitogenic signals initiated by Ras signaling
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become dispensable when Cic is mutated (Tseng et al.
2007; Jin et al. 2015).
In contrast, the role of mammalian Cic has been less
well characterized. However, it has been shown that
MAPK signaling also regulates the repressor activity of
human CIC proteins. Likewise, ERK and its downstream
substrate, p90RSK, can phosphorylate human CIC, there-
by interfering with its nuclear import and DNA-binding
capabilities, respectively (Dissanayake et al. 2011). Fur-
thermore, CIC has been implicated in several human pa-
thologies. For instance, CIC is known to form nuclear
complexes with Ataxin 1 (ATXN1) and Ataxin 1-like
(ATXN1L, also known as BOAT [brother of Ataxin 1])
(Lam et al. 2006). ATXN1 is a glutamine-rich protein im-
plicated in spinocerebellar ataxia type 1 (SCA1), and ex-
pansion of its polyglutamine tract, which is known to
cause SCA1, alters the repressive properties of CIC
(Crespo-Barreto et al. 2010). These results suggest that
ATXN1 and ATXN1L act as Cic corepressors in mam-
mals. Indeed, expression of polyglutamine-expanded
ATXN1 causes deregulation of a subset of CIC target
genes. Moreover, mice lacking both Atxn1 and Atxn1L
show destabilization of Cic proteins accompanied by up-
regulation of Cic target genes such as the Pea3 family
members Etv4 or Etv5 (Lee et al. 2011). As a consequence,
these mice display a series of developmental defects such
as omphalocele and lung alveolarization deficiencies.
Mutations in CIC have been identified recently in sev-
eral human cancers. The highest incidence of mutated
CIC is found in oligodendrogliomas (53%–69%), where
one allele is usually lost upon loss of heterozygosity
(LOH) of chromosomes 1p and 19q, and the other is affect-
ed by missense or nonsense mutations (Bettegowda et al.
2011; Yip et al. 2012). Likewise, CIC mutations have
also been identified, albeit at lower frequency, in several
other malignancies, such as stomach adenocarcinomas
(12.9%), endometrial carcinomas (6.9%), colorectal carci-
nomas (6.1%), or melanomas (5.2%) (Cerami et al. 2012;
Gao et al. 2013). Thesemutations appear to be a late event
during tumorigenesis and have been found to promote
metastases (Okimoto et al. 2017). Most missense muta-
tions in CIC cluster into codons encoding the HMG-box
or the C1motif, thus interfering with CIC’s DNA-binding
abilities and causing derepression of its target genes (Forés
et al. 2017). Other mutations produce premature stop
codons, altered splice sites, and frameshift insertions or
deletions that are also thought to inactivate CIC’s repres-
sor function.
To better understand the role of Cic in mammals, we
generated a genetically engineered mouse model express-
ing defective Cic proteins that cannot bind DNA and
hence repress expression of its target genes. Our data
show that Cic is an essential gene in mouse development
and that systemic disruption of Cic DNA binding in adult
mice causes T-cell acute lymphoblastic lymphoma (T-
ALL). We also show that human T-ALL carrying muta-
tions in the RAS/MAPK pathway displays a genetic sig-
nature indicative of CIC inactivation, thus suggesting
that CIC inactivation plays a key role in this human
malignancy.
Results
Generation of mice carrying inactive Cic alleles
To genetically analyze the role ofCic inmammals, we de-
cided to generate amouse strain carrying conditional loss-
of-function (LOF) Cic alleles. To this end, we introduced
loxP sequences flanking exons 2–6 by homologous recom-
bination (Fig. 1A; Supplemental Fig. S1A). These exons en-
code the highly conserved HMG-box (Supplemental Fig.
S1B), a domain required for DNA binding and hence re-
pressor activity (Jiménez et al. 2012; Forés et al. 2017).
Elimination of exons 2–6 maintains the Cic ORF, direct-
ing the synthesis of mutant Cic-L and Cic-S isoforms
that lack 288 amino acids, a region that includes the
HMG-box (Fig. 1B). In this study, the conditional allele
is designated as Ciclox, whereas the recombined allele is
designated asCicΔ2–6, and its gene products are designated
as CicΔ2–6. To confirm that deletion of exons 2–6 elimi-
nates Cic activity, we engineered a human CIC-S cDNA
lacking those sequences corresponding to exons 2–6 fused
to a GFP tag (Fig. 1C,D). The resulting GFP-CICΔ2–6 pro-
tein completely lacks the ability to bind to the promoters
of well-known CIC target genes such as CCND1 (Cyclin
D1) and the PEA3 family of transcription factors ETV1,
ETV4, and ETV5, as demonstrated by chromatin immuno-
precipitation (ChIP) assays using full-length GFP-CIC-S as
a positive control (Fig. 1E).
Cic activity is essential for late embryonic development
To assess the role of Cic in development, we generated
germline Cic+/Δ2–6 mice by mating Cic+/lox animals (see
the Supplemental Material) with EIIa-Cre transgenic
mice that express the bacterial Cre recombinase in their
zygotes (Lakso et al. 1996). Heterozygous Cic+/Δ2–6 ani-
mals were viable and did not show obvious defects for
up to 1 yr of age. Homozygous CicΔ2–6/Δ2–6 embryos
were present at Mendelian ratios at embryonic day 18.5
(E18.5). However, E18.5 CicΔ2–6/Δ2–6 embryos were signif-
icantly smaller than their wild-type or heterozygous
counterparts and died immediately after birth (Fig. 2A).
Most of these embryos (70%) presented an omphalocele,
an abdominal wall closure defect (Fig. 2B). Omphaloceles
occur naturally during mammalian development when
the gut transiently herniates the umbilical space due to
limited space in the peritoneal cavity (Doyonnas et al.
2001). This structure is usually resolved by E16 in mice,
thus indicating that Cic function may be required for re-
traction of the gut from the umbilical cord. Interestingly,
a similar phenotype was observed in embryos lacking the
Cic corepressorsAtxn1 andAtxn1L, an observation attrib-
uted to the decrease of Cic protein levels in Atxn1−/−;
Atxn1L−/− mice (Lee et al. 2011). CicΔ2–6/Δ2–6 embryos
did not display hydrocephali, another phenotype frequent-
ly detected in Atxn1−/−;Atxn1L−/− mice (Lee et al. 2011).
In addition, we could not analyze whether lung alveolari-
zation was affected, as shown previously in mice lacking
the Cic-L isoform (Lee et al. 2011), since CicΔ2–6/Δ2–6
embryos died right after birth. However, expression of
Capicua is a tumor suppressor in mice
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matrix metalloproteases known to be responsible for de-
fective lung alveolarization was not affected at E18.5, al-
though Cic target genes were markedly derepressed
(Supplemental Fig. S2A,B).
Further characterization of E18.5 CicΔ2–6/Δ2–6 embryos
revealed a dramatic increase in proliferating (Ki67+) lung
cells, suggesting a defect in terminal differentiation of
the respiratory epithelium (Fig. 2C; Supplemental Fig.
S2C). Immunohistochemistry (IHC) studies involving
γH2AX and active Caspase 3 failed to reveal signs of
DNA damage or increased apoptosis (Supplemental Fig.
S2D). To determine whether terminal differentiation of
the lung is affected in CicΔ2–6/Δ2–6 embryos, we analyzed
lung differentiation markers by IHC. E18.5 CicΔ2–6/Δ2–6
embryos displayed persistent TTF-1 (also known as
Nkx2-1) expression levels in a high proportion of epitheli-
al cells, a phenotype reminiscent of lungs in the canalicu-
lar stage (Naltner et al. 2000;Moreno-Barriuso et al. 2006),
which suggests delayed or altered alveolar maturation
(Fig. 2C). Consistent with this defect, we detected reduced
expression levels of SP-C, amarker of type II alveolar cells,
and increased periodic acid Schiff (PAS) staining, thus
demonstrating that the lungs ofCicΔ2–6/Δ2–6 embryos can-
not produce sufficient amounts of surfactant for postnatal
life (Fig. 2C).
Cic inactivation in mouse embryonic fibroblasts (MEFs)
MEFs obtained from E13.5CicΔ2–6/Δ2–6 embryos displayed
the same proliferative properties as wild-type MEFs
(Supplemental Fig. S3A). As expected, homozygous ex-
pression of CicΔ2–6 proteins resulted in derepression of
Cic target genes, such as those encoding the Pea3 family
of transcription factors (Supplemental Fig. S3B,C). Like-
wise, we did not detect significant differences in the acti-
vation of the MAPK or PI3K signaling pathways
(Supplemental Fig. S3D). In addition, CicΔ2–6/Δ2–6 MEFs
are as efficiently transformed as wild-type MEFs by H-
RasG12V and E1A but not by E1A alone, thus suggesting
that Cic inactivation does not phenocopy Ras activation
in MEFs (Supplemental Fig. S3E,F). These results indicate
that Cic proteins do not play an important role in normal
cell proliferation, at least in MEFs.
Previous studies have demonstrated that ablation of Cic
activity in the Drosophila eye imaginal disc as well as in
intestinal stem cells sustains proliferation in the absence
of Ras (Tseng et al. 2007; Jin et al. 2015). To test whether
inactivation of Cic could sustain cell proliferation in
MEFs devoid of Ras proteins, we generated H-Ras−/−;N-
Ras−/−;K-Raslox/lox and H-Ras−/−;N-Ras−/−;K-Raslox/lox;
Ciclox/lox MEFs. These cells were infected with adenoviral
particles expressing the Cre recombinase in order to ab-
late K-Ras expression and generate “Rasless” cells. These
Rasless cells failed to proliferate regardless of whether
they retained Cic repressor activity (Supplemental Fig.
S3G). These results indicate that Ras signaling must be
mediated by additional effectors, at least in MEFs.
Cic inactivation in the brain is not sufficient to initiate
oligodendroglioma development
Human oligodendrogliomas often display losses of chro-
mosomes 1p and 19q. Recently, the CIC locus, located
in 19q, has been found to be mutated in these tumors
Figure 1. CicΔ2–6 proteins cannot bind toCic target genepromot-
ers. (A) Schematic representation of the targetedmouseCic locus.
Exons corresponding to Cic-L and Cic-S proteins are indicated.
Coding exons are indicated by filled boxes, and noncoding exons
are indicated by open boxes. LoxP sites are depicted as red trian-
gles. (B) Representation of intact Cic-L and Cic-S proteins (top)
and corresponding mutant products after Cre-mediated recombi-
nation (bottom). Exon 1A (unique to Cic-L) is indicated by blue
boxes, and exon 1B (present only in Cic-S) is indicated by red box-
es. (C ) Schematic representation of human CIC-S and CIC-SΔ2–6
proteins fused to GFP. Sequences encoded by exon 1B (red boxes)
and theGFP tag (green boxes) are shown. (D)Western blot analysis
ofGFP-CIC-S andGFP-CIC-SΔ2–6 (Δ2–6) proteins expressed in Flp-
In T-REx 293 cells. Protein expression was detected using anti-
GFPantibodies.As a control, cellswere transfectedwith anempty
vector (vector). GAPDHexpression served as a loading control. (E)
ChIP assay using GFP antibodies in Flp-In T-REx 293 cells stably
expressing GFP-CIC-S (blue bars) or GFP-CIC-SΔ2–6 (black bars).
Flp-In T-REx 293 cells stably transfected with an empty vector
were used as a control (red bars). Specificity of GFP immunopre-
cipitations was validated using an unrelated antibody (mock). As-
sociation with the CIC-binding elements in the ETV1, ETV4,
ETV5, andCCND1 promoters aswell as binding to theCDK1 pro-
moter lacking known CIC-binding sites (negative control) were
analyzed by quantitative RT–PCR and normalized to the amount
of input DNA. Data represent mean ± SD.
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following a mutational pattern indicative of LOF, thus
suggesting that CIC may act as a tumor suppressor
(Bettegowda et al. 2011; Yip et al. 2012). To determine
whether inactivation of CIC is sufficient to initiate
oligodendroglioma development, we crossed Ciclox/lox
mice with a strain expressing the Cre recombinase under
the control of the human glial fibrillary acidic protein
promoter (hGFAP-Cre) (Zhuo et al. 2001). This strain
expresses Cre in the central nervous system from E13.5
onward, resulting in efficient recombination in cells de-
rived from GFAP-positive progenitors, such as neurons,
astrocytes, and oligodendrocytes (Casper and McCarthy
2006). Indeed, crossing the hGFAP-Cre mice with the
Rosa26LSLlacZ reporter strain (Mao et al. 1999) revealed
efficient recombination in most if not all cells of the
brain (Supplemental Fig. S4A). hGFAP-Cre-mediated re-
combination of Ciclox alleles did not result in tumor for-
mation even at 1 yr of age. Indeed, we could not detect
any significant alterations in the brain at the histopatho-
logical level despite efficient recombination of Ciclox
alleles followed by significant derepression of Cic target
genes such as Etv4 and Etv5 (Supplemental Fig. S4B,C).
These observations indicate that Cic inactivation in the
brain does not initiate oligodendroglioma formation,
thus suggesting the need for other cooperating events in
this tumor type.
Cic inactivation in adult mice causes T-cell
lymphoblastic lymphoma
CIC mutations have also been identified in a variety of
other human tumors (Cerami et al. 2012; Gao et al.
2013). Hence, we decided to systemically inactivate Cic
in adult mice. To this end, we crossed Ciclox/lox animals
with mice carrying a transgene encoding a ubiquitously
expressed CreERT2 recombinase (hUBC-CreERT2)
(Ruzankina et al. 2007). Continuous exposure of these
compound mice to a tamoxifen (Tmx) diet from 4 wk of
age resulted in efficient recombination ofCiclox alleles af-
ter 3 mo of treatment (Supplemental Fig. S5A,B). At this
time, mice expressing the inactive CicΔ2–6 proteins
throughout most of their tissues were normal and did
not show obvious phenotypes at the histopathological
level. However, when we subjected Ciclox/lox;hUBC-
CreERT2+/T mice for longer times to the Tmx diet, most
of them (92%) died before 1 yr of age, with a median sur-
vival of 36 wk (Fig. 3A). Characterization of these mice
at a humane end point revealed dramatically enlarged thy-
muses (Fig. 3B). No other tissue displayed detectable alter-
ations. Further analysis revealed the presence of T-cell
lymphoblastic lymphomas (T-ALL) as indicated by CD3
IHC staining on the cell surface and moderate expression
of the terminal deoxynucleotidyl transferase (TDT) (Fig.
3C). Moreover, these tumors displayed a prominent popu-
lation of CD4/CD8 double-positive cells, although the
levels of single CD4+ and CD8+ cells were variable, as sug-
gested by immunophenotyping of three different tumors,
indicating that the tumors harbored features of immature
T cells from cortical stages (Fig. 3D; Belver and Ferrando
2016). In most cases, tumor cells also spread to other or-
gans, including the lungs, liver, and spleen, and could be
transplanted into immunodeficient mice (Supplemental
Fig. S6A,B). Consistent with these observations, the tu-
mors harbored monoclonal or oligoclonal T-cell receptor
(TCR) rearrangements, indicating clonal expansion of tu-
mor cells (Fig. 3E).
Similar transcriptional profiles in T-ALL induced
by Cic inactivation and Ras oncogenes
Tounderstand themolecular bases of T-ALL development
induced by ablation of Cic activity, we performed tran-
scriptional profiling analysis of these tumors by RNA se-
quencing (RNA-seq). As illustrated in Supplemental
Figure S7A and Supplemental Table S1, we detected sig-
nificant overexpression of 55 genes and down-regulation
Figure 2. Cic repressor activity is essential for
mouse development. (A) Body weight of Cic+/+,
Cic+/Δ2–6, and CicΔ2–6/Δ2–6 embryos at E18.5. Data
represent mean ± SD. Asterisks depict statistically
significant differences. (∗) P < 0.05; (∗∗∗) P < 0.001,
unpaired Student’s t-test. (B) Representative images
of Cic+/+ (left) and CicΔ2–6/Δ2–6 (middle) embryos at
E18.5. (Right) Hematoxilin and eosin (H&E) stain-
ing of a whole CicΔ2–6/Δ2–6 embryo section at
E18.5. Bar, 2 mm. Arrowheads indicate omphalo-
celes. (C ) H&E, Ki67, TTF-1, and SP-C immunohis-
tochemistry (IHC) as well as periodic acid Schiff
(PAS) staining in lung sections of Cic+/+ and
CicΔ2–6/Δ2–6 embryos at E18.5. Bars: H&E, Ki67,
TTF-1, and SP-C, 50 µm; PAS stainings, 25 µm. In-
lays in PAS stainings represent magnifications.
Capicua is a tumor suppressor in mice
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of 181 loci (log2 fold change≥ +3 or log2 fold change≤−3;
adjusted P-value < 0.05). As expected, the well-known Cic
target genes Etv4 and Etv5 were among the 30 most up-
regulated genes in these tumors. Next, we interrogated
whether the transcriptional profiles of these tumors re-
semble those induced by Ras oncogenes (Kindler et al.
2008; Sabnis et al. 2009), including those present in
KHRasV12 mice, a strain that expresses an oncogenic H-
RasG12V protein from the K-Ras locus (Drosten et al.
2017). Analysis by RNA-seq followed by principal compo-
nent analysis (PCA) of gene expression profiles of H-
RasG12V and Cic inactivation-induced T-ALLs revealed
significant overlaps (Fig. 4A,B). In contrast, similar tumors
obtained from p53−/− mice (Jacks et al. 1994) were clearly
distinct. These results suggest that Ras oncoproteins and
inactivation of Cic induced T-ALL by similar mecha-
nisms. Notably, Cic target gene expression also depends
on Ras signaling in normal thymuses, thus suggesting
that the Cic repressor activity is regulated by Ras signal-
ing in normal thymuses (Supplemental Fig. S7B).
A common event in T-ALL development is hyperactiva-
tion of the Notch signaling pathway (Belver and Ferrando
2016). Indeed, all H-RasG12V or Cic inactivation-driven
tumors show activation of the Notch pathway based on
IHC staining of cleaved Notch1 and its target, Hes1
(Supplemental Fig. S8A,B; Drosten et al. 2017). Moreover,
we detected a significant enrichment of a transcriptional
signature indicative of Notch pathway activation
(Supplemental Fig. 8C; Liberzon et al. 2015). Previous
data have shown that T-ALL driven by K-RasG12D carries
frequent mutations in Notch1 that were not tumorigenic
on their own but cooperated with the activated Ras onco-
gene to induce T-ALL (Chiang et al. 2008). RNA-seq anal-
ysis of five tumors induced uponCic inactivation revealed
only a rare miscoding mutation (A1639T) in one of the tu-
mors, thus suggesting that Notch pathway activation oc-
curred mostly via other mechanisms.
Growth of Cic-induced T-ALL is independent of MAPK
activation
Next, we interrogated whether T-ALL tumors induced by
inactivation of Cic proteins require an active MAPK sig-
naling pathway. These tumors, unlike those induced by
H-RasG12V expression, did not display elevated levels of
Erk phosphorylation (Fig. 5A). Next, we treated tumor
cells derived from both CicΔ2–6/Δ2–6- and H-RasG12V-driv-
en tumors with GSK1120212 (trametinib), a selective
MEK inhibitor that effectively blocks MAPK signaling
driven by Ras oncogenes (Wright and McCormack 2013).
As illustrated in Figure 5, A and B, trametinib effectively
blocked MAPK signaling as well as proliferation of H-
RasG12V-driven tumor cells. In contrast, this MEK inhibi-
tor had no effect on proliferation of tumor cells driven by
Cic inactivation. These results demonstrate that Cic inac-
tivation occurs downstream from Ras signaling in T-ALL.
Furthermore, they also predict that human tumors carry-
ing inactivating mutations in the CIC locus are likely to
be resistant to inhibitors of the MAPK pathway (see
below).
Tumor induction by Cic inactivation is mediated
by the Etv4 transcription factor
As indicated above, some of themain targets of Cic are the
genes encoding members of the Pea3 family of transcrip-
tion factors: Etv1, Etv4, and Etv5 (Kawamura-Saito et al.
2006; Dissanayake et al. 2011). Hence, we examined
Figure 3. Cic inactivation in adult mice causes T-ALL. (A) Tu-
mor-free survival of Cic+/+;hUBC-CreERT2+/T (black dots; n =
13) or Ciclox/lox;hUBC-CreERT2+/T (white dots; n = 11) mice sub-
jected to a continuous Tmx diet at 4 wk of age. (B) Representative
image of the thoracic cavity of a Ciclox/lox;hUBC-CreERT2+/T
mouse treated for 8mowith aTmxdiet and sacrificed at ahumane
endpoint. (C ) H&E aswell asCD3orTDT IHCstaining of thymus
sections obtained fromCic+/+;hUBC-CreERT2+/Tmice at 6mo of
age or Ciclox/lox;hUBC-CreERT2+/T mice at a humane end point.
Bar, 50 µm. (D) Representative flow cytometry analyses of CD4+
and CD8+ cells in thymuses obtained from Cic+/+;hUBC-
CreERT2+/T mice at 6 mo of age or Ciclox/lox;hUBC-CreERT2+/T
mice at a humane end point. (E) Abundance of TCR clonotypes
in three independent T-ALL tumors obtained from Tmx-treated
Ciclox/lox;hUBC-CreERT2+/T mice (tumors 1–3) or a representa-
tive thymus from a Cic+/+;hUBC-CreERT2+/T mouse (wild type).
The relative abundance of each clonotype is shown, calculated
as the abundanceof each clonotype relative to the total abundance
of all clonotypes of the same TCR chain in a sample. Clonotypes
are plotted in lexicographical order. The read abundance of each
clonotype is represented by the size of the symbol (large symbols,
1:1,000,000; small symbols, 1:10,000,000). Clonotypes deter-
mined to be dominant are shown in orange. (Circles) α TCR
chains; (triangles) β TCR chains; (cross) γ TCR chains; (X) ambig-
uous TCR chains.
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whether any of these proteins might be responsible for
mediating tumor induction upon inactivation of Cic.
Since Etv4was the genemost up-regulated in cells lacking
activeCic repression, we introduced Etv4-deficient alleles
(Etv4NLZ/NLZ) (Livet et al. 2002) into Ciclox/lox;UBC-
CreERT2+/T mice. As illustrated in Figure 5C, reduced ex-
pression of Etv4 in Ciclox/lox;Etv4+/NLZ;UBC-CreERT2+/T
animals had no effect on tumor development, since all of
themice developed T-ALLwith a median survival similar
to that of animals carrying wild-type Etv4 alleles. Howev-
er, complete ablation of Etv4 dramatically prevented the
induction of T-ALL upon inactivation of Cic. Indeed,
four of five Ciclox/lox;Etv4NLZ/NLZ;UBC-CreERT2+/T
mice had no signs of thymic disease by 1 yr of age, a
time when all Ciclox/lox;Etv4+/+;UBC-CreERT2+/T ani-
mals had already succumbed to the disease. Only one
out of these five mice displayed limited tumor formation
by 1 yr of age, indicating that tumor growth was dramati-
cally delayed. These results strongly indicate that Etv4 is a
key mediator of the tumorigenic consequences of Cic in-
activation. Notably, absence of Etv4 did not per se affect
normal thymocyte development (Fig. 5D,E). Interestingly,
CicΔ2–6/Δ2–6;Etv4NLZ/NLZ tumor cells displayed increased
levels of Etv5 and, to a lesser extent, Etv1 expression, in-
dicating that in the absence of Etv4, Etv5 is the primary
member of the Pea3 family to respond to Cic inactivation
(Fig. 5F). However, this increased expression is not suffi-
cient to induce T-ALL, at least in most mice. Whether
concomitant ablation of Etv4 and Etv5 expression will
completely block T-ALL development or whether overex-
pression of Etv4 alone is sufficient to cause T-ALL re-
mains to be determined.
Identification of a gene signature indicative of CIC
inactivation in mouse and human T-ALL
Human T-ALL has been classified based on transcription-
al profiling. Work by Ferrando et al. (2002) identified gene
signatures that correspond to specific stages of T-cell de-
velopment. We compared these human T-ALL signatures
with expression data obtained from T-ALL tumors in-
duced by either H-RasG12V expression or Cic inactivation.
As illustrated in Supplemental Figure S8D, tumors in-
duced by Cic inactivation were highly enriched for the
TLX1+ signature (also known asHOX11+), thus suggesting
that these tumors share features of human T-ALL arrested
at the early cortical stage (Belver and Ferrando 2016). In
agreement with the PCA data, H-RasG12V-driven tumors
also displayed enrichment of this signature but to a slight-
ly lesser degree. These observations suggest that tumors
driven by Ras oncogenes should display a transcriptional
signature indicative of Cic inactivation. To this end, we
first established a Cic LOF gene signature based on genes
that carried evolutionarily conserved Cic-binding sites
and became derepressed in tumors induced by Cic inacti-
vation. Specifically, we selected a 32-gene signature (Cic
LOF signature CIC_LOF_4) based on genes that were up-
regulated at least a log2 fold change of 1.5 and harbored
at least one Cic-binding sequence (CBS) (Kawamura-
Saito et al. 2006) with a conservation score of >0.875
in their promoters (see the Supplemental Material;
Supplemental Fig. S9A; Supplemental Table S2). Next,
we performed unsupervised clustering of the independent
T-ALL tumor samples using this Cic LOF signature. As il-
lustrated in Figure 6A, Cic LOF- and H-RasG12V-induced
tumors formed a common cluster. Although they did
not cluster with the aforementioned tumors, p53-null tu-
mors showed a limited enrichment of the Cic LOF signa-
ture (Supplemental Fig. S9B). These observations indicate
that Cic target genes are derepressed in H-RasG12V-driven
tumors, suggesting that hyperactive Ras signaling causes
inactivation of Cic to promote T-ALL.
We next wanted to interrogate whether the Cic LOF
gene signature derived from ourmurine T-ALL expression
data is conserved in humanT-ALL samples harboring acti-
vation of the RAS/MAPK/CIC axis. To this end, we took
advantage of a published T-ALL data set that includes
geneexpression andmutationdata from31T-ALLpatients
Figure 4. Similar transcriptional profiles in
T-ALL driven by Cic inactivation or Ras
hyperactivation. (A) PCA of gene expression
profiles obtained from wild-type thymuses
(black dots) and T-ALLs developed in Tmx-
treated Ciclox/lox;hUBC-CreERT2+/T (red
dots), KHRasV12;hUBC-CreERT2+/T (green
dots), or p53−/− mice (blue dots) at a humane
end point. (B) Heat map displaying differen-
tially expressed genes (log2 fold change≥ +3
or log2 fold change≤−3; adjusted P-value <
0.05; false discovery rate [FDR] 0.05) as esti-
mated by RNA-seq from samples shown in
A. Relative expression (log2 fold change) is
scaled in color (as indicated) from dark blue
(−3) to dark red (+3). Gene symbols are listed
in Supplemental Table S1.
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and 18 T-ALL cell lines (Atak et al. 2013). We selected
those samples that carried either a mutation in CIC or
any other alteration that predicts CIC inactivation via ac-
tivation of the MAPK pathway, such as mutations in
NRAS, KRAS, NF1, or PTK2B. In addition, we included
samples carrying the NUP214-ABL1 or SSBP2-FER fu-
sions, since their activated tyrosine kinases are known to
induce MAPK activation. Following this strategy, we as-
sembled 16 out of the 49 samples into a group that was ex-
pected to harbor inactive CIC via one of the mechanisms
described above (Fig. 6B). Since our Cic LOF signature de-
rived frommouse tumors was composed of only 32 genes,
we did not find enrichment of this restricted signature in
the RAS/MAPK/CIC sample group. However, when we
used a more relaxed signature composed of 143 genes
that were significantly up-regulated in Cic LOF-driven T-
ALL and contained at least one CBS (CIC_LOF_3)
(SupplementalTable S3; Supplemental Fig. S9A),we found
this signature to be significantly enriched in the RAS/
MAPK/CIC sample group (Fig. 6C). In addition, we found
theTLX1+ signature to be enriched in this group of 16 sam-
ples, providing further evidence for the similarity between
human andmouse tumors (Fig. 6C). Taken together, these
data indicate that human T-ALL samples driven by the
RAS/MAPK/CIC axis and mouse tumors driven by H-
RasG12V expression or Cic inactivation share a gene signa-
ture characteristic of CIC inactivation.
CIC inactivation in human T-ALL causes resistance to
MAPK inhibition
Sequencing analysis of primary T-ALL clinical specimens
revealed the presence of CIC mutations in 10% (n = 7 of
69) of cases analyzed (Supplemental Fig. S10A–C). Other
studies also identifiedCICmutations, albeit at a lower fre-
quency (Supplemental Fig. S10D; Atak et al. 2013;
Kataoka et al. 2015). These mutations are predicted to
cause resistance toMAPK inhibition, similar to our obser-
vation in murine T-ALL cells. To test this hypothesis, we
first determined the sensitivity of a variety of human T-
ALL cell lines to trametinib. Notably, exposure to trame-
tinib had no effect in CCRFCEM and JURKAT cells
(Supplemental Fig. S11A,B). In contrast, MOLT4 and
HSB2 cells were sensitive to this MEK inhibitor. To
Figure 5. MurineT-ALL driven byCic inactivation is resistant toMEK inhibition and requires Etv4. (A)Western blot analysis of p-Erk1/2
and total Erk1/2 in T-ALL cells obtained from tumors developed in Tmx-treated KHRasV12;hUBC-CreERT2+/T (left) or Ciclox/lox;hUBC-
CreERT2+/T (right) mice treated with the indicated concentrations of trametinib for 24 h. GAPDH expression served as a loading control.
(B) Growth curve of T-ALL cells obtained from tumors developed in Tmx-treated KHRasV12;hUBC-CreERT2+/T (left) or Ciclox/lox;hUBC-
CreERT2+/T (right) mice treated with the indicated concentrations of trametinib for the indicated time. (C ) Tumor-free survival
of Ciclox/lox;Etv4+/NLZ;hUBC-CreERT2+/T (open dots; n = 11) or Ciclox/lox;Etv4NLZ/NLZ;hUBC-CreERT2+/T (closed dots; n = 5) mice sub-
jected to a continuous Tmx diet starting at 4 wk of age. (D) Percentage of thymocyte populations in 1-mo-old wild-type (open bars; n = 3)
or Etv4NLZ/NLZ (closed bars; n = 3) mice. CD4/CD8-double-negative, CD4/CD8-double-positive, CD4-single-positive, and CD8-single-
positive populations are shown. Data represent mean ± SD. (E) Percentage of CD4/CD8 double-negative (DN) thymocyte subpopula-
tions in 1-mo-old wild-type (open bars; n = 3) or Etv4NLZ/NLZ (closed bars; n = 3) mice. DN1 (CD44+/CD25−), DN2 (CD44+/CD25+),
DN3 (CD44−/CD25+), and DN4 (CD44−/CD25−) subpopulations are shown. Data represent mean ± SD. (F ) Relative expression levels of
Etv1, Etv4, and Etv5 mRNAs in wild-type thymuses (open bars; n = 2); T-ALLs developed in Tmx-treated Ciclox/lox;hUBC-CreERT2+/T
mice (CicΔ2–6/Δ2–6; red bars; n = 2); or the only tumor that developed in Tmx-treated Ciclox/lox;Etv4NLZ/NLZ;hUBC-CreERT2+/T mice
(CicΔ2–6/Δ2–6;Etv4NLZ/NLZ; closed bars). β-Actin expression levels were used for normalization. Data represent mean ± SD.
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interrogate whether CIC activity determines sensitivity
toMAPK pathway inhibition, we focused onMOLT4 cells
(known to carry mutated N-Ras) and disabled CIC via
Crispr/Cas9-mediated gene editing using two different
single-guide RNAs (sgRNAs). Indeed, as illustrated in Fig-
ure 7A–C, MOLT4 cells lacking CIC became resistant to
trametinib treatment, indicating that CIC inactivation
confers resistance to MAPK inhibition in human T-ALL.
ETV4 expression is required for human T-ALL cell lines
Finally, our data indicate that Etv4 expression is required
for T-ALL development induced by Cic inactivation in
mice. To analyzewhether ETV4 is also required for growth
of human T-ALL cells, we inhibited ETV4 expression in
CCRFCEM, JURKAT, MOLT4, and HSB2 cells with two
independent shRNAs. As indicated in Figure 7, D and E,
ETV4 expression is required for efficient proliferation of
these cell lines independently of the mutational status of
CIC or RAS. These observations suggest that ETV4 plays
a relevant role in murine and human T-ALL. In summary,
these data indicate that the same genes and mechanisms
operate to induce T-ALL in mice and humans.
Discussion
Cic is a transcriptional repressor negatively regulated by
MAPK signaling that is known to play essential roles dur-
ing development of Drosophila embryos (Jiménez et al.
2000, 2012; Astigarraga et al. 2007). In contrast, the role
of Cic in mammalian development has not been thor-
oughly studied. Zoghbi and coworkers (Fryer et al. 2011;
Lee et al. 2011) used a gene trap approach to generate a
strain that expresses only the Cic-S isoform (Cic-L−/−).
Most Cic-L−/− mice died before weaning, and those that
survived postnatal development were of smaller size and
presented lung alveolarization defects, a phenotype simi-
lar to that ofmice lacking the Cic corepressorAtxn1L (Lee
et al. 2011).
In this study, we completely ablatedCic repressor activ-
ity by targeting exons 2–6 of the Cic locus, a domain
Figure 6. Agene signature indicative of Cic LOF is enriched inmouse and humanT-ALL driven by inactivation of Cic or activation of the
Ras/MAPK pathway. (A) Heat map generated by unsupervised clustering of differentially expressed genes present in a 32-gene Cic LOF
signature (CIC_LOF_4), as estimated by RNA-seq from wild-type thymuses and T-ALLs developed in Tmx-treated Ciclox/lox;hUBC-
CreERT2+/T as well as KHRasV12;hUBC-CreERT2+/T mice or p53−/− animals at a humane end point. Gene symbols are indicated, and rel-
ative expression (log2 fold change) is scaled in color (as indicated) from dark blue (−3) to dark red (+3). (B) Indication of pointmutations and
gene fusions present in a published data set of humanT-ALL samples (fromAtak et al. 2013). Samples carrying protein-alteringmutations
and fusions that are predicted to activate the RAS/MAPK/CIC axis are indicated in dark blue, and those harboring mutations affecting
other pathways are indicated in light blue. The mutations affecting specific genes in each sample are indicated in red (only for the
RAS/MAPK/CIC group). NUP214-ABL1 and SSBP2-FER represent gene fusions identified in selected samples. Mutations in NOTCH1
are indicated in green. The SUPT1 cell line harbors a gene fusion that causes overexpression of NOTCH1 (light green). (C ) Enrichment
plot showing significant enrichment (FDR < 25%) of a 143-gene signature indicative of CIC LOF (CIC_LOF_3; left) or a TLX1+
(HOX11+; right) gene signature in human T-ALL samples predicted to have an active RAS/MAPK/CIC axis (from B). (NES) Normalized
enrichment score.
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encoding the HMG-box required for DNA binding and re-
pressor activity of both Cic isoforms, Cic-L and Cic-S. As
expected, the truncated CicΔ2–6 proteins did not bind to
the promoters of their target genes. When Cic activity
was inactivated in the germline, none of the CicΔ2–6/Δ2–6
mice survived after birth despite being present at Mende-
lian ratios at E18.5. We detected dramatic defects in lung
maturation, thus suggesting that these immature lungs
were primarily responsible for the perinatal lethality in
CicΔ2–6/Δ2–6 mice. However, we could not assess the pres-
ence of lung alveolarization defects such as those ob-
served in surviving Cic-L−/− and Atxn1L−/− animals
because lung alveolarization occurs at later stages of post-
natal life.
The majority of E18.5 CicΔ2–6/Δ2–6 embryos (70%) also
presented omphaloceles, a phenotype observed in
Atxn1−/−;Atxn1L−/− mice (Lee et al. 2011), thus suggest-
ing that the Cic/Atxn1 or Cic/Atxn1L complex is essen-
tial for the regulation of abdominal wall closure.
However, our CicΔ2–6/Δ2–6 embryos did not recapitulate
all of the defects present in Atxn1−/−;Atxn1L−/− mice.
For instance, we did not observe hydrocephali, suggesting
that Atxn1/Atxn1L proteins may possess Cic-indepen-
dent functions. Alternatively, the different phenotypes
may be explained by low residual levels of Cic proteins
in Atxn1−/−;Atxn1L−/− mice (Lee et al. 2011).
Previous studies have shown that Cic inactivation in
the eye imaginal disc and adult intestinal stem cells in
Drosophila rescues the proliferation defects caused by ab-
lation of the single Ras gene (Tseng et al. 2007; Jin et al.
2015). This indicates that Cic is a key mediator that con-
nects MAPK signaling with the transcriptional program
required to process mitogenic signals. However, ablation
of Cic activity in cells lacking the three Ras isoforms
failed to restore their proliferative properties, indicating
that Ras mitogenic signals must be mediated by addition-
al components of the transcriptional machinery, at least
in these cells.
CIC is recurrently mutated in human oligodendroglio-
mas. These tumors display mutations in one CIC allele,
whereas the other is lost as part of larger 19q chromosom-
al deletions, suggesting thatCIC functions as a tumor sup-
pressor (Bettegowda et al. 2011; Yip et al. 2012). However,
selective inactivation of Cic proteins in the mouse brain
was not sufficient to drive oligodendroglioma formation.
As illustrated here, selective expression of inactive Cic
proteins in most brain cells, including neuronal and glial
precursors derived from hGFAP-Cre-expressing progeni-
tors, failed to induce any detectable alterations in 1-yr-
old mice. In human oligodendrogliomas, CIC is always
comutatedwith IDH1 or IDH2 (Yip et al. 2012) or, less fre-
quently, FUBP1, thus raising the possibility that tumor
formation requires cooperation of these cancer genes
withCIC (Bettegowda et al. 2011). Interestingly, Idh1mu-
tant mice also fail to develop brain tumors (Sasaki et al.
2012). Finally, it should also be noted thatCICmutations
are not always maintained in recurrent oligodendroglio-
mas, arguing that these mutations may be subclonal sec-
ondary events that do not necessarily provide a growth
advantage for tumor cells (Aihara et al. 2017).
Conditional inactivation of Cic proteins in adult mice
resulted in the development of T-ALL after 6–9 mo with
almost complete penetrance (>90%), thus demonstrating
that Cic can act as a tumor suppressor in mice. These tu-
mors were significantly enriched in the TLX1+ signature,
thus suggesting that Cic inactivation causes thymocyte
arrest at the early cortical stage (Belver and Ferrando
2016). Interestingly, Cic is likely a target of the Tlx1 re-
pressor, a fact that raises the possibility that Tlx1-mediat-
ed repression of Cic plays a role in T-ALL development
induced by this transcriptional repressor (De Keers-
maecker et al. 2010; Della Gatta et al. 2012). However,
Figure 7. Resistance to MEK inhibition and requirement for
ETV4 expression in human T-ALL cell lines. (A) Western blot
analysis of p-ERK1/2 and total ERK1/2 expression in MOLT4
cells treated with the indicated concentrations of trametinib for
24 h. GAPDH expression served as a loading control. (B) Western
blot analysis of CIC expression levels in MOLT4 cells 2 wk after
infection with lentiviruses expressing Cas9 and the indicated
sgRNAs. GAPDH expression served as a loading control. (C ) Pro-
liferation of MOLT4 cells 2 wk after infection with lentiviruses
expressing Cas9 and the indicated sgRNAs and treated with the
indicated concentrations of trametinib. (D) Proliferation of
CCRFCEM, JURKAT, HSB2, andMOLT4 cells infected with len-
tiviruses expressing two independent shRNAs targeting ETV4 or
a nontargeting control. (E) Relative ETV4 mRNA expression lev-
els in 293T cells infected with lentiviruses expressing a control
shRNA or two different shRNAs against ETV4.
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the functional relevance of this pathway for T-ALL devel-
opment remains to be determined.
T-ALL development via activation of Ras oncogenes
has also been described in mouse tumor models (Kindler
et al. 2008; Sabnis et al. 2009). More recently, we observed
T-ALL in mice that express the H-RasG12V oncoprotein
driven from the K-Ras promoter (Drosten et al. 2017).
These tumors are indistinguishable from those induced
upon Cic inactivation. Indeed, the gene expression pro-
files of tumors induced byH-RasG12V expression or Cic in-
activation are highly similar. Hence, we propose that a
significant proportion of gene expression changes in Ras-
driven T-ALL occurs via inactivation of Cic. Likewise, a
gene signature indicative of Cic inactivation was highly
enriched in Ras-driven T-ALL.More importantly, this sig-
nature is also significantly enriched in human T-ALL
samples harboring mutations that are predicted to cause
aberrant signaling through the RAS/MAPK/CIC axis.
These observations indicate that CIC acts downstream
from the RAS/MAPK pathway in T-ALL. Although RAS
mutations are not frequent in these cancers (∼5%), it
has been suggested that up to 50% of all human T-ALL
cases have aberrant RAS signaling (von Lintig et al.
2000). In addition, RAS/MAPK-activating mutations are
much more prevalent in relapsed T-ALL (Oshima et al.
2016), thus suggesting that CIC inactivation through hy-
peractive Ras signalingmay play a relevant role in a signif-
icant number of T-ALL cases.
However, these T-ALL tumors may present different
responses to pharmacological inhibition of the MAPK
pathway. For instance, tumors that developed as a conse-
quence of K-RasG12D activation in mice are sensitive to
Mek inhibition (Dail et al. 2010). Likewise, as demonstrat-
ed here, tumor cells derived from lymphomas driven by
H-RasG12V expression could be efficiently inhibited upon
exposure to the MEK inhibitor trametinib. However, T-
ALLs that arose upon Cic inactivation were completely
resistant to this inhibitor, indicating that mutations in
this locus activate mitogenic signaling downstream
from the MAPK cascade. Indeed, CIC inactivation in hu-
man T-ALL cell lines also caused resistance to MEK inhi-
bition. Hence, CIC mutations may develop as a potential
mechanism of resistance to MAPK inhibitors. Of note,
mutations in CIC have been identified in human T-ALL,
albeit at a low frequency (Atak et al. 2013; Kataoka et al.
2015; this study). Consistent with our observations, CIC
has been identified recently in a screen to detect novel
mechanisms that cause resistance to trametinib in other
tumor models (Wang et al. 2017). Similarly, CIC has also
been identified in a screen for genes whose absence pro-
motes resistance to EGFR inhibition (Liao et al. 2017).
Finally, Bivona and colleagues (Okimoto et al. 2017) have
shown that CIC inactivation is associated with advanced
tumor stages andmetastasis formation in lung and gastric
tumors, thus suggesting that these tumors may be intrin-
sically resistant to MEK or EGFR inhibition.
The emerging role of CIC mutations in human cancers
makes it necessary to understand the mechanisms that
mediate its repressor activity. As indicated above, the
best-known CIC targets are the members of the PEA3
family of transcription factors: ETV1, ETV4, and ETV5.
However, the functional consequences of inhibiting CIC
repression in human tumors are unknown. Here, we pro-
vide genetic evidence that in T-ALL induced by inactiva-
tion of Cic proteins, the main Cic effector is the
transcription factor Etv4. Indeed, ablation of Etv4 expres-
sion in Cic inactivation-induced T-ALL completely pre-
vented the development of this disease in four out of
five mice and significantly delayed tumor formation in
the remaining animal. Notably, thymocyte development
was not altered in Etv4-deficient mice, indicating that
Etv4 (and possibly other Pea3 family members such as
Etv5) is selectively required for tumor formation.Whether
Etv4 is also required for Ras-driven T-ALL remains to be
determined. However, similar observations were made
upon depletion of ETV4 in human T-ALL cell lines, al-
though growth inhibition appears to be independent of
the mutational status of CIC or RAS. Thus, a better
understanding of the molecular events triggered by CIC
inactivation should providemore effective therapeutic ap-
proaches to treat those human tumors driven by either
RAS hyperactivation or CIC mutations.
Materials and methods
Mice
ThehUBC-CreERT2 (Ruzankinaetal. 2007),EIIa-Cre (Laksoetal.
1996), p53−/− (Jacks et al. 1994), hGFAP-Cre (Zhuo et al. 2001),
Etv4NLZ/NLZ (Livet et al. 2002), H-Ras−/−;N-Ras−/−;K-Raslox/lox
(Drosten et al. 2010), and KHRasV12 (Drosten et al. 2017) strains
have been described previously. Activation of the inducible
CreERT2 recombinase was achieved by feeding the mice with a
Tmx-containing diet (Harlan Laboratories). All mice were main-
tained in a mixed 129/Sv-C57BL/6 background. For tumor cell
transplantation assays, single-cell suspensions (106 cells per 200
µL of PBS) were injected into the tail veins of immunodeficient
mice. All animal experiments were approved by the Ethical Com-
mittees of the Spanish National Cancer Research Centre (CNIO),
the Carlos III Health Institute, and the Autonomous Community
of Madrid and were performed in accordance with the guidelines
stated in the International Guiding Principles for Biomedical Re-
search Involving Animals, developed by the Council for Interna-
tional Organizations of Medical Sciences (CIOMS).
Cell lines
MEFs were extracted from E13.5 embryos and cultured in DMEM
supplemented with 10% FBS. T-ALL cell lines established from
tumor-bearing mice and human T-ALL cell lines were propagated
in RPMI1640 supplemented with 10% FBS. For growth inhibition
assays, murine cells were seeded at a density of 2 × 105 cells per
milliliter with various concentrations of trametinib. Human cell
lines were seeded in 96-well plates at a density of 10,000 cells
per well, and proliferation was assessed using the (4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay (Roche).
Plasmids
The GFP-tagged human CIC-S construct in pcDNA5/FRT/TO
(Dissanayake et al. 2011) was a kind gift of Dr. Carol MacKintosh
(University of Dundee, UK). The deletion of exons 2–6 (spanning
residues 24–311) was introduced using the QuikChange site-
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directed mutagenesis kit (Agilent) following the manufacturer’s
guidelines. All plasmids were stably introduced into Flp-In T-
REx 293 cells (Invitrogen) following instructions from the manu-
facturer. Human CIC targeting sgRNAs (#1, CCCCTCCGTGC
AGCCGAGCG; #2, GCCTCGCTCGGCTGCACGGA) or a non-
targeting control sgRNA (CTCGTGAACAAGATCCGAC) were
cloned into lentiCRISPRv2 (Addgene 52961). Sigma MISSION
shRNA lentiviral vectors were used to knock down ETV4 expres-
sion in human cell lines (#232, TRCN0000013937; and #736,
TRCN0000013934). A nontargeting shRNA vector (SHC002)
was used as control.
Histopathology and IHC
For histological analyses, tissues were fixed in 10% buffered for-
malin and embedded in paraffin. Hematoxilin and eosin (H&E)
staining and IHC analyses were performed on 3-µm paraffin sec-
tions. For IHC, the following antibodies were used: CD3 (Phar-
mingen, 553057), cleaved Notch1 (Abcam, ab8925), Hes1
(CNIO), TDT (DAKO, A3524), Ki67 (Master Diagnostica,
0003110QD), γH2AX (Millipore, 05-636), and active Caspase 3
(Cell Signaling, 9661). PAS staining was performed by incubation
for 5 min with periodic acid followed by 20 min of incubation
with Schiff reagent and hematoxylin counterstaining.
Western blot analysis
Western blot analysis of protein extracts obtained from tissues,
cell lines, or MEFs was performed as described (Drosten et al.
2010). To specifically probe for Cic expression levels, protein ex-
tracts were prepared in TST buffer as described (Lam et al. 2006).
Primary antibodies used included polyclonal Cic antisera for the
mouse proteins (Lam et al. 2006; Kim et al. 2015), human CIC
(Abcam, ab123822), pErk1/2 (Cell Signaling Technology, 9101),
pAkt (Cell Signaling Technology, 9271), Akt (Cell Signaling
Technology, 9272), Erk1 (Santa Cruz Biotechnology, C16), and
GAPDH (Sigma-Aldrich, G8795).
Flow cytometry analysis
Thymocytes were obtained by mechanical dissociation of the
thymus in RPMI1640. Before analysis, cells were preincubated
with purified anti-mouse CD16/32 antibodies (1:200; BD Phar-
mingen) for 15 min on ice to block nonspecific Fc receptor-medi-
ated binding. Aliquots of 5 × 106 cells were stained for 20 min at
room temperature with the following monoclonal antibodies:
PECy7 α-Gr1 (1:200), BUV737 α-CD19 (1:400), APCCy7 α-
Ter119 (1:200), PE α-Nk1.1/α-DX5 (1:200; to exclude non T cells),
FITC α-CD4 (1:800), BUV395 α-CD8 (1:400), APC α-CD44 (1:200),
and PerCPCy5.5 α-CD25 (1:200). Samples were processed on a
LSRFortessa flow cytometer (BD Pharmingen) and analyzed using
FlowJo (Tree Star).
Statistical analysis
Data are mean ± SD for Figures 1E, 5D–F, and 7C–E. Comparison
between different genotypes in Figure 2B was performed using an
unpaired Student’s t-test. P-values of <0.05 were considered to be
statistically significant (P < 0.05 [∗] and P < 0.001 [∗∗∗]).
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